• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chemomab Therapeutics Ltd ADR (NQ: CMMB )

    1.650 +0.050 (+3.12%)
    Streaming Delayed Price Updated: 3:55 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 42,387
    Open 1.600
    Bid (Size) 1.620 (5)
    Ask (Size) 1.790 (30)
    Prev. Close 1.600
    Today's Range 1.580 - 1.680
    52wk Range 0.4200 - 2.550
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +206.81%
    +206.81%
    1 Month
    +6.45%
    +6.45%
    3 Month
    +17.86%
    +17.86%
    6 Month
    +89.66%
    +89.66%
    1 Year
    +197.30%
    +197.30%

    More News

    Read More
    Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    Earnings Scheduled For November 14, 2024
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics to Present at October 2024 Investor Conferences
    From Chemomab Therapeutics
    Via GlobeNewswire
    Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Chemomab Therapeutics to Present at September 2024 Investor Conferences
    From Chemomab Therapeutics
    Via GlobeNewswire
    CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
    Via InvestorPlace
    Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Announces Closing of $10 Million Private Placement
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
    Via Benzinga
    Chemomab Therapeutics Announces $10 Million Private Placement
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
    From Chemomab Therapeutics
    Via GlobeNewswire
    CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
    Via InvestorPlace
    Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
    From Chemomab Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
    From Chemomab Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.